Breast Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Breast Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 3 (2006), Issue 2 (February)

1. The Brn-3b POU family transcription factor represses plakoglobin gene expression in human breast cancer cells.
   Int J Cancer, 118(4): 869-78. [Abstract] [Full-text]
2. Steroid hormone receptors and coregulators in endocrine-resistant and estrogen-independent breast cancer cells.
   Int J Cancer, 118(4): 832-40. [Abstract] [Full-text]
3. Vascular endothelial growth factor-D is a survival factor for human breast carcinoma cells.
   Int J Cancer, 118(4): 841-9. [Abstract] [Full-text]
4. The steroid receptor RNA activator protein is expressed in breast tumor tissues.
   Int J Cancer, 118(4): 1054-9. [Abstract] [Full-text]
5. Enhancing the antitumor activity of ErbB blockade with histone deacetylase (HDAC) inhibition.
   Int J Cancer, 118(4): 1041-50. [Abstract] [Full-text]
6. Inefficient proteasomal-degradation pathway stabilizes AP-2alpha and activates HER-2/neu gene in breast cancer.
   Int J Cancer, 118(4): 802-11. [Abstract] [Full-text]
7. Trastuzumab and antiestrogen therapy: focus on mechanisms of action and resistance.
   Am J Clin Oncol, 29(1): 90-5. [Abstract] [Full-text]
8. Does breast size affect the scatter dose to the ipsilateral lung, heart, or contralateral breast in primary breast irradiation using intensity-modulated radiation therapy (IMRT)?
   Am J Clin Oncol, 29(1): 80-4. [Abstract] [Full-text]
9. Impact of Her-2 Neu overexpression on outcome of elderly women treated with wide local excision and breast irradiation for early stage breast cancer: an exploratory analysis.
   Am J Clin Oncol, 29(1): 71-9. [Abstract] [Full-text]
10. Intensity modulated radiation therapy (IMRT) decreases acute skin toxicity for women receiving radiation for breast cancer.
    Am J Clin Oncol, 29(1): 66-70. [Abstract] [Full-text]
11. Therapeutic mammaplasty for centrally located breast tumors.
    Plast Reconstr Surg, 117(2): 366-73. [Abstract] [Full-text]
12. Implant reconstruction in breast cancer patients treated with radiation therapy.
    Plast Reconstr Surg, 117(2): 359-65. [Abstract] [Full-text]
13. Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial.
    JAMA, 295(6): 629-42. [Abstract] [Full-text]
14. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer.
    J Clin Oncol, 24(5): 769-77. [Abstract] [Full-text]
15. DeltaTAp73 upregulation correlates with poor prognosis in human tumors: putative in vivo network involving p73 isoforms, p53, and E2F-1.
    J Clin Oncol, 24(5): 805-15. [Abstract] [Full-text]
16. Suppression of survival in human SKBR3 breast carcinoma in response to metal-chelator complexes is preferential for copper-dithiocarbamate.
    Biochem Pharmacol, 71(6): 722-34. [Abstract] [Full-text]
17. Retinoids interfere with the AP1 signalling pathway in human breast cancer cells.
    Cell Signal, 18(6): 889-98. [Abstract] [Full-text]
18. FGFR4 GLY388 isotype suppresses motility of MDA-MB-231 breast cancer cells by EDG-2 gene repression.
    Cell Signal, 18(6): 783-94. [Abstract] [Full-text]
19. Pegylated liposomal doxorubicin in combination with gemcitabine: a phase II study in anthracycline-naïve and anthracycline pretreated metastatic breast cancer patients.
    Cancer Chemother Pharmacol, 57(5): 615-23. [Abstract] [Full-text]
20. Failure of neutrophil chemotactic function in breast cancer patients treated with chemotherapy.
    Cancer Chemother Pharmacol, 57(5): 663-70. [Abstract] [Full-text]
21. Oral vinorelbine alone or in combination with trastuzumab in advanced breast cancer: results from a pilot trial.
    Cancer Chemother Pharmacol, 57(5): 554-8. [Abstract] [Full-text]
22. CYP1A1 activation of aminoflavone leads to DNA damage in human tumor cell lines.
    Cancer Chemother Pharmacol, 57(5): 569-76. [Abstract] [Full-text]
23. Phase I/II dose escalation study of angiotensin 1-7 [A(1-7)] administered before and after chemotherapy in patients with newly diagnosed breast cancer.
    Cancer Chemother Pharmacol, 57(5): 559-68. [Abstract] [Full-text]
24. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis.
    J Natl Cancer Inst, 98(4): 262-72. [Abstract] [Full-text]
25. Differential expression of novel naturally occurring splice variants of PTEN and their functional consequences in Cowden syndrome and sporadic breast cancer.
    Hum Mol Genet, 15(5): 777-87. [Abstract] [Full-text]
26. Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models.
    Cancer Chemother Pharmacol, 57(5): 693-702. [Abstract] [Full-text]
27. High efficacy of gemcitabine and cisplatin in patients with predominantly anthracycline- and taxane-pretreated metastatic breast cancer.
    Cancer Chemother Pharmacol, 57(5): 640-6. [Abstract] [Full-text]
28. BACH1 Ser919Pro variant and breast cancer risk.
    BMC Cancer, 6: 19. [Abstract] [Full-text]
29. Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer.
    J Clin Oncol, 24(6): 910-7. [Abstract] [Full-text]
30. Community-based use of chemotherapy and hormonal therapy for early-stage breast cancer: 1987-2000.
    J Clin Oncol, 24(6): 872-7. [Abstract] [Full-text]
31. Characterization of BRCA1 and BRCA2 mutations in a large United States sample.
    J Clin Oncol, 24(6): 863-71. [Abstract] [Full-text]
32. Identification in administrative databases of women dying of breast cancer.
    J Clin Oncol, 24(6): 856-62. [Abstract] [Full-text]
33. Randomized trial of long-term follow-up for early-stage breast cancer: a comparison of family physician versus specialist care.
    J Clin Oncol, 24(6): 848-55. [Abstract] [Full-text]
34. Male breast cancer.
    Lancet, 367(9510): 595-604. [Abstract] [Full-text]
35. New methods give better estimates of changes in diagnostic accuracy when prior information is provided.
    J Clin Epidemiol, 59(3): 299-307. [Abstract] [Full-text]
36. Angiosarcoma after conservation treatment for breast carcinoma: our experience and a review of the literature.
    J Am Acad Dermatol, 54(3): 499-504. [Abstract] [Full-text]
37. UDP-N-acetyl-D-galactosamine: polypeptide N-acetylgalactosaminyltransferase-6 as a new immunohistochemical breast cancer marker.
    J Histochem Cytochem, 54(3): 317-28. [Abstract] [Full-text]
38. Immunohistochemical analysis of MUC5B apomucin expression in breast cancer and non-malignant breast tissues.
    J Histochem Cytochem, 54(3): 289-99. [Abstract] [Full-text]
39. Survival rates for breast cancers detected in a community service screening mammogram program.
    Am J Surg, 191(3): 406-9. [Abstract] [Full-text]
40. Sentinel lymph node dissection for breast cancer: how many nodes are enough and which technique is optimal?
    Am J Surg, 191(3): 330-3. [Abstract] [Full-text]
41. Osteoprotegerin (OPG)--a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis?
    Int J Cancer, 118(8): 1901-8. [Abstract] [Full-text]
42. Comparison of the clinical significance of occult tumor cells in blood and bone marrow in breast cancer.
    Int J Cancer, 118(8): 2013-9. [Abstract] [Full-text]
43. Estradiol and its metabolites 4-hydroxyestradiol and 2-hydroxyestradiol induce mutations in human breast epithelial cells.
    Int J Cancer, 118(8): 1862-8. [Abstract] [Full-text]
44. Quantitative analysis of aromatase mRNA expression derived from various promoters (I.4, I.3, PII and I.7) and its association with expression of TNF-alpha, IL-6 and COX-2 mRNAs in human breast cancer.
    Int J Cancer, 118(8): 1915-21. [Abstract] [Full-text]
45. Seventy-five years is an appropriate upper age limit for population-based mammography screening.
    Int J Cancer, 118(8): 2020-5. [Abstract] [Full-text]
46. Tubal sterilization in relation to breast cancer risk.
    Int J Cancer, 118(8): 2026-30. [Abstract] [Full-text]
47. A prospective study of breast size and premenopausal breast cancer incidence.
    Int J Cancer, 118(8): 2031-4. [Abstract] [Full-text]
48. Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer.
    Br J Cancer, 94(4): 524-31. [Abstract] [Full-text]
49. FADD phosphorylation is critical for cell cycle regulation in breast cancer cells.
    Br J Cancer, 94(4): 532-9. [Abstract] [Full-text]
50. Prevalence of serologic reactivity against four strains of mouse mammary tumour virus among US women with breast cancer.
    Br J Cancer, 94(4): 548-51. [Abstract] [Full-text]
51. Expression of human Kallikrein 14 (KLK14) in breast cancer is associated with higher tumour grades and positive nodal status.
    Br J Cancer, 94(4): 540-7. [Abstract] [Full-text]
52. Prognostic impact of multidrug resistance gene expression on the management of breast cancer in the context of adjuvant therapy based on a series of 171 patients.
    Br J Cancer, 94(4): 473-80. [Abstract] [Full-text]
53. Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen?
    Br J Cancer, 94(4): 460-4. [Abstract] [Full-text]
54. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment.
    Blood, 107(5): 1761-7. [Abstract] [Full-text]
55. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.
    N Engl J Med, 354(8): 809-20. [Abstract] [Full-text]
56. Study protocol to investigate the effect of a lifestyle intervention on body weight, psychological health status and risk factors associated with disease recurrence in women recovering from breast cancer treatment [ISRCTN08045231].
    BMC Cancer, 6: 35. [Abstract] [Full-text]
57. Magnetic resonance-guided, vacuum-assisted breast biopsy: results from a European multicenter study of 538 lesions.
    Cancer, 106(5): 982-90. [Abstract] [Full-text]
58. Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy.
    Cancer, 106(5): 1000-6. [Abstract] [Full-text]
59. Landmark trials in endocrine adjuvant therapy for breast carcinoma.
    Cancer, 106(5): 975-81. [Abstract] [Full-text]
60. Long-term cosmetic results and toxicity after accelerated partial-breast irradiation: a method of radiation delivery by interstitial brachytherapy for the treatment of early-stage breast carcinoma.
    Cancer, 106(5): 991-9. [Abstract] [Full-text]
61. Association of the CASP10 V410I variant with reduced familial breast cancer risk and interaction with the CASP8 D302H variant.
    Carcinogenesis, 27(3): 606-9. [Abstract] [Full-text]
62. The joint effect of smoking and AIB1 on breast cancer risk in BRCA1 mutation carriers.
    Carcinogenesis, 27(3): 599-605. [Abstract] [Full-text]
63. Association of genetic variants in the Rho guanine nucleotide exchange factor AKAP13 with familial breast cancer.
    Carcinogenesis, 27(3): 593-8. [Abstract] [Full-text]
64. N-(4-Hydroxyphenyl)retinamide and nitric oxide pro-drugs exhibit apoptotic and anti-invasive effects against bone metastatic breast cancer cells.
    Carcinogenesis, 27(3): 568-77. [Abstract] [Full-text]
65. Growth inhibition of carcinogen-transformed MCF-12F breast epithelial cells and hormone-sensitive BT-474 breast cancer cells by 1alpha-hydroxyvitamin D5.
    Carcinogenesis, 27(3): 551-9. [Abstract] [Full-text]
66. Lymphocytes of BRCA1 and BRCA2 germ-line mutation carriers, with or without breast cancer, are not abnormally sensitive to the chromosome damaging effect of moderate folate deficiency.
    Carcinogenesis, 27(3): 517-24. [Abstract] [Full-text]
67. Risk of second cancer among women with breast cancer.
    Int J Cancer, 118(9): 2285-92. [Abstract] [Full-text]
68. Development in incidence of breast cancer in non-screened Danish women, 1973-2002--a population-based study.
    Int J Cancer, 118(9): 2366-9. [Abstract] [Full-text]
69. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update.
    Int J Cancer, 118(9): 2281-4. [Abstract] [Full-text]
70. Tissue microarrays for comparing molecular features with proliferation activity in breast cancer.
    Int J Cancer, 118(9): 2190-4. [Abstract] [Full-text]
71. Long-term survival of T1 and T2 lymph node-negative breast cancer patients according to Mitotic Activity Index: a population-based study.
    Int J Cancer, 118(9): 2310-4. [Abstract] [Full-text]
72. The intraductal approach to breast cancer biomarker discovery.
    J Clin Oncol, 24(7): 1209-16. [Abstract] [Full-text]
73. Social networks, social support, and survival after breast cancer diagnosis.
    J Clin Oncol, 24(7): 1105-11. [Abstract] [Full-text]
74. Advanced breast cancer patients' perceptions of decision making for palliative chemotherapy.
    J Clin Oncol, 24(7): 1090-8. [Abstract] [Full-text]
75. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032.
    J Clin Oncol, 24(7): 1052-6. [Abstract] [Full-text]
76. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.
    J Clin Oncol, 24(7): 1037-44. [Abstract] [Full-text]
77. Drug treatments for adjuvant chemotherapy in breast cancer: recent trials and future directions.
    Expert Rev Anticancer Ther, 6(3): 427-36. [Abstract] [Full-text]
78. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study.
    J Clin Oncol, 24(7): 1045-51. [Abstract] [Full-text]
79. Prospective study of wide excision alone for ductal carcinoma in situ of the breast.
    J Clin Oncol, 24(7): 1031-6. [Abstract] [Full-text]
80. Clinical experience with a 3D surface patient setup system for alignment of partial-breast irradiation patients.
    Int J Radiat Oncol Biol Phys, 64(4): 1265-74. [Abstract] [Full-text]
81. A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer: final results.
    Int J Radiat Oncol Biol Phys, 64(4): 1072-80. [Abstract] [Full-text]
82. Cause-specific mortality in long-term survivors of breast cancer: A 25-year follow-up study.
    Int J Radiat Oncol Biol Phys, 64(4): 1081-91. [Abstract] [Full-text]
83. Initial dosimetric experience using simple three-dimensional conformal external-beam accelerated partial-breast irradiation.
    Int J Radiat Oncol Biol Phys, 64(4): 1092-9. [Abstract] [Full-text]

© 2004-2008 Breast Cancer Research Today. All Rights Reserved.